患者选择深度大脑刺激,以治疗泛氨酸激酶相关的神经退行症
Jason L Chan1,2, Ashley E Rawls1,2, Joshua K Wong1,2
1Norman Fixel Institute for Neurological Diseases, University of Florida, Gainesville, Florida, USA.
Tremor and other hyperkinetic movements (New York, N.Y.)
|October 21, 2024
概括
深度大脑刺激 (DBS) 在患有泛酸酶相关神经退行症 (PKAN) 的患者中改善了通用性 dystonia 和步态. 这种好处持续了一年多,为管理这种罕见的神经退行性疾病提供了希望.
科学领域:
- 神经科学是一个神经科学.
- 神经学 神经学
- 医疗技术 医疗技术 医学技术
背景情况:
- 潘托酸酶相关的神经退行症 (PKAN) 是一种罕见的神经退行性疾病.
- 在PKAN中,通用性 dystonia 和步行障碍是常见的,通常是药物耐药的症状.
- 深度大脑刺激 (DBS) 是一种成熟的 dystonia 治疗方法,但其在 PKAN 中的疗效是可变的.
研究的目的:
- 为了评估双边全球内体 (GPi) DBS在PKAN患者中治疗药物耐药性 dystonia 的长期有效性.
- 评估GPi DBS对PKAN中步行障碍的影响.
- 为PKAN中DBS的有限证据基础做出贡献,特别是在长期结果方面.
主要方法:
- 一个23岁的女性PKAN的案例研究,呈现出泛性 dystonia 和步行障碍.
- 进行了双边GPi DBS植入.
- 临床结果,包括 dystonia 严重程度和步行功能,在植入后的一年多时间内进行了监测.
主要成果:
- 双边的GPi DBS导致了普遍性 dystonia 的显著改善.
- 在DBS后,观察到走路障碍明显改善.
- 在 dystonia 和步态上,DBS 的治疗效果持续了一年多.
结论:
- 双边GPi DBS可以作为PKAN中全身 dystonia和步行障碍的有效治疗方法,即使在药物耐药的情况下也是如此.
- DBS的积极影响可以是持久的,提供持续的功能改善.
- 虽然PKAN在DBS后进展,但谨慎的患者选择和关于步态和姿势稳定的咨询对于管理期望至关重要.
更多相关视频
14:14Targeting Neuronal Fiber Tracts for Deep Brain Stimulation Therapy Using Interactive, Patient-Specific Models
Published on: August 12, 2018
8.8K
06:32Author Spotlight: Automated Deep Brain Stimulation for Parkinson's Disease - Exploring the Possibilities and Challenges of Home Monitoring
Published on: July 14, 2023
1.2K
相关概念视频
01:26Psychosis: Goals of Pharmacotherapy
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...